| Trial ID: | L6338 |
| Source ID: | NCT03155087
|
| Associated Drug: |
Metformin
|
| Title: |
PRKAA2 Genetic Polymorphisms and Its Susceptibility to Chinese Type 2 Diabetes Mellitus and Diabetic Nephropathy
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
T2DM (Type 2 Diabetes Mellitus)
|
| Interventions: |
DRUG: Metformin
|
| Outcome Measures: |
Primary: the incidence of T2DM, people whose fasting plasma glucose ≥7.0 mmol/L and/or postprandial plasma glucose ≥11.1 mmol/L is diagnosed with T2DM., Jan 2014-Dec 2015 | Secondary: metformin efficacy----the decrease level of HbA1c, patients whose HbA1c levels is decreased by more than 0.5 % from the baseline is deemed as the response group, while the decrease in HbA1c levels less than 0.5 % from the baseline is deemed as the non-response group., Jan 2014-Dec 2015
|
| Sponsor/Collaborators: |
Sponsor: People's Hospital of Zhengzhou University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
750
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2013-06
|
| Completion Date: |
2015-12
|
| Results First Posted: |
|
| Last Update Posted: |
2017-05-16
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT03155087
|
